| Caitlin Schauer, | |
|
4407 116th St Ne, Marysville, WA 98271-8568 | |
| (360) 965-1649 | |
| Not Available |
| Full Name | Caitlin Schauer |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 4407 116th St Ne, Marysville, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285182675 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | LL 60636348 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Caitlin Schauer, 12422 42nd Ave Ne, Marysville, WA 98271-8701 Ph: () - | Caitlin Schauer, 4407 116th St Ne, Marysville, WA 98271-8568 Ph: (360) 965-1649 |
News Archive
Nephros, Inc., a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced the completion of its rights offering and private placement that together will result in gross proceeds of approximately $3.2 million to Nephros.
NovaBay Pharmaceuticals, Inc. today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial. This dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or MRSA. Impetigo afflicts approximately 1 million people, primarily infants and children, in the United States annually.
Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, has completed a Phase 3 clinical trial of Lymphoseek® (NEO3-05) with positive results.
W. L. Gore & Associates (Gore) today announced it has received European CE Mark approval for an expanded indication of the GORE® VIABIL® Biliary Endoprosthesis that allows removal of the device up to 12 months after implantation for the treatment of benign or malignant biliary strictures. The GORE® VIABIL® Biliary Endoprosthesis first received CE Mark approval in December 1999 and U.S. Food and Drug Administration (FDA) approval in January 2002 for the treatment of biliary strictures due to malignant neoplasms.
› Verified 8 days ago
Deborah Bradley, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4220 80th St Ne, Marysville, WA 98270 Phone: 360-653-0896 | |
Dr. Paul Morphy, PHD CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6325 91st St Ne, Marysville, WA 98270 Phone: 360-965-1966 | |
Graham Lucas Chattin, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4220 80th St Ne, Marysville, WA 98270 Phone: 360-965-0000 | |
Miss Barbara Andrea Herrera Rojas, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 14500 51st Ave Ne, Marysville, WA 98271 Phone: 360-965-8687 | |
Marysville School District Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4220 80th Street Ne, Marysville School District, Marysville, WA 98270 Phone: 360-653-7058 Fax: 360-657-6824 | |
Maryann Walters, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4220 80th St Ne, Marysville, WA 98270 Phone: 360-653-7058 |